COMPARATIVE STUDY OF EFFICACY OF LOW-DOSE CONTINUOUS AND LOW-DOSE INTERMITTENT ORAL ISOTRETINOIN THERAPY IN MODERATE ACNE VULGARIS

N NOOR; S SALEEM; TA MUJAHID; MU GHANI

doi:10.54112/pjicm.v5i02.132

Authors

N NOOR Department of Dermatology, CMH Nowshera, Pakistan
S SALEEM Department of Dermatology, CMH Nowshera, Pakistan
TA MUJAHID Department of Dermatology, CMH, Peshawar, Pakistan
MU GHANI Department of Ophthalmology, CMH Mardan, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i02.132

Keywords:

Moderate Acne Vulgaris, Oral Isotretinoin, Low-Dose Therapy, Continuous Regimen, Intermittent Regimen, Treatment Efficacy

Abstract

Background: Acne vulgaris is a common dermatological condition that significantly affects quality of life. Isotretinoin is the most effective treatment for moderate-to-severe cases. Still, concerns regarding dosing strategies and adverse effects have led to investigations into alternative regimens such as low-dose continuous and intermittent therapies. Objective: To compare the efficacy of low-dose continuous and low-dose intermittent oral isotretinoin therapy in patients with moderate acne vulgaris. Study Design: Quasi-experimental design. Setting: Department of Dermatology, Combined Military Hospital, Nowshera, Pakistan. Duration of Study: 08-February-2025 to 08-June-2025. Methods: A total of 112 participants aged 18–60 years with clinically diagnosed moderate acne vulgaris were enrolled and equally allocated into two groups (n=56 each). Group A received continuous oral isotretinoin (20 mg once daily for 2 months), while Group B received intermittent oral isotretinoin (20 mg once daily for 1 week per 4-week cycle over 2 months). Efficacy was defined as at least a 10-point reduction in Global Acne Grading System (GAGS) score from baseline to 2 months. An independent t-test was applied to compare pre- and post-treatment GAGS scores, with a significance threshold set at p ≤ 0.05. Results: The mean age of participants was 30.71 ± 10.13 years in Group A and 29.43 ± 8.55 years in Group B. Following treatment, mean GAGS scores were 10.43 ± 5.53 in Group A and 8.75 ± 5.99 in Group B. No statistically significant difference was observed between the groups (p = 0.12). Both regimens demonstrated clinically meaningful improvement. Conclusion: Low-dose continuous and low-dose intermittent oral isotretinoin therapies are similarly effective for the management of moderate acne vulgaris. Both regimens can be considered safe and effective alternatives in clinical practice.

References

Monib KM, El-fallah AA, Salem RM. Inflammatory markers in acne vulgaris: saliva as a novel diagnostic fluid. J Cosmet Dermatol. 2022;21(3):1280-5. https://doi.org/10.1111/jocd.14236

Vasam M, Korutla S, Bohara RA. Acne vulgaris: a review of the pathophysiology, treatment, and recent nanotechnology-based advances. Biochem Biophys Rep. 2023;36:101578. https://doi.org/10.1016/j.bbrep.2023.101578

Zhu W, Wang HL, Bu XL, Zhang JB, Lu YG. A narrative review of research progress on the role of NLRP3 inflammasome in acne vulgaris. Ann Transl Med. 2022;10(11):645. https://doi.org/10.21037/atm-21-5924.

Fallah H, Rademaker M. Isotretinoin in the management of acne vulgaris: practical prescribing. Int J Dermatol. 2021;60(4):451-60. https://doi.org/10.1111/ijd.15089

Zhu Z, Zhong X, Luo Z, Liu M, Zhang H, Zheng H, et al. Global, regional, and national burdens of acne vulgaris in adolescents and young adults aged 10–24 years from 1990 to 2021: a trend analysis. Br J Dermatol. 2025;192(2):228-37. https://doi.org/10.1093/bjd/ljae352

Heng AH, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. https://doi.org/10.1038/s41598-020-62715-3

Raznatovic Durovic M, Jankovic J, Durovic M, Spiric J, Jankovic S. Adolescents' beliefs and perceptions of acne vulgaris: a cross-sectional study in Montenegrin schoolchildren. PLoS One. 2021;16(6):e0253421. https://doi.org/10.1371/journal.pone.0253421

George RM, Sridharan R. Factors aggravating or precipitating acne in Indian adults: a hospital-based study of 110 cases. Indian J Dermatol. 2018;63(4):328-31. https://doi.org/10.4103/ijd.IJD_565_17

Alsohaimi AO, Alghamdi A, Alghamdi RS, Alghamdi AH, Alkhathami AM, Alghamdi MA, et al. Prevalence of acne vulgaris in adolescents and young adults in Al-Baha Region, Saudi Arabia. Cureus. 2024;16(10):e71293. https://doi.org/10.7759/cureus.71293

Villani A, Nastro F, Di Vico F, Fabbrocini G, Annunziata MC, Genco L. Oral isotretinoin for acne: a complete overview. Expert Opin Drug Saf. 2022;21(8):1027-37. https://doi.org/10.1080/14740338.2022.2102605

Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-30. https://doi.org/10.1016/j.jaad.2023.12.017

Zaenglein AL, Segal J, Darby C, Del Rosso JQ. Lidose-isotretinoin administered without food improves quality of life in patients with severe recalcitrant nodular acne: an open-label, single-arm, phase IV study. J Clin Aesthet Dermatol. 2020;13(9):15-20.

Shetti SA, Nagesh HN, Hanumantharaya N. A randomized, open-label, comparative study of the efficacy of low-dose continuous versus low-dose intermittent oral isotretinoin therapy in moderate-to-severe acne vulgaris. Natl J Physiol Pharm Pharmacol. 2017;7(9):941-6. https://doi.org/10.5455/njppp.2017.7.0305804052017

Niazi S, Shehzad A. Comparison of efficacy of fixed low-dose regimens (daily vs alternate day) of oral isotretinoin in mild to moderate acne vulgaris. J Pak Assoc Dermatol. 2015;25(4):291-7.

Maheshwari RA, Makwana S, Sisara H, Rajput HS, Trivedi R, Sen AK, et al. Clinical profiles, prescription trends, and quality of life in young adults with acne vulgaris: a cross-sectional study in a tertiary care teaching hospital. J Young Pharm. 2025;17(2):463-9. https://doi.org/10.5530/jyp.20251592

Al-Dhubaibi MS. Treatment of mild to moderate acne with conventional versus two different intermittent doses and continuous low-dose isotretinoin: a randomized, comparative study. J Adv Med Med Res. 2016;13(3):1-7. https://doi.org/10.9734/BJMMR/2016/23594

Faghihi G, Mokhtari F, Motamedi Fard N, Motamedi N, Hosseini SM. Comparing the efficacy of low-dose and conventional-dose oral isotretinoin in the treatment of moderate and severe acne vulgaris. J Res Pharm Pract. 2017;6(4):233-8. https://doi.org/10.4103/jrpp.JRPP_17_30

Faysal LR, Iqbal R, Fatima B. Effectiveness of oral intermittent vs oral continuous isotretinoin therapy in patients with moderate to severe acne vulgaris: a randomized controlled trial. J Islam Int Med Coll. 2022;17(1):14-8.

Rehman F, Pirzada DA, Abdullah S, Khan MA. Open-label study comparing the efficacy of continuous low-dose isotretinoin versus intermittent low-dose isotretinoin regimens in moderate to severe acne vulgaris. J Ayub Med Coll Abbottabad. 2025;37(2). https://doi.org/10.55519/JAMC-01-13671

Hafeez L, Khan AN, Aslam A, Tahir R, Shafi A, Akhtar A. Comparison of safety and efficacy of low-dose isotretinoin versus the conventional dosing regime in the treatment of acne vulgaris. J Pak Assoc Dermatol. 2020;30(3):423-7.